Tracking how well a medicine works in Alzheimer’s patients
Part of Brain & nervous system, Mental health clinical trials.
This study looks at how effective a treatment is in people newly diagnosed with mild to moderate Alzheimer’s disease. It also involves health and medication history checks and likely stool (fecal) sample collection to monitor effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be age 65 or older
- Have a new diagnosis of mild or moderate dementia from Alzheimer’s
- Have not started Alzheimer’s memory medicines yet (or stopped within the last 3 months only because of side effects)
- Live in the National Capital Region and be able to read and understand English and Filipino
- Have a brain CT scan that does not suggest other main causes of dementia (except for small “lacunes,” 2 or fewer)
- Be free of certain stomach and bowel issues and avoid certain medicines/foods around the time of stool sample collection
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study compares two different ways of prescribing cholinesterase inhibitors (common Alzheimer's medications) to see which works better over time. If you or your loved one has mild to moderate Alzheimer's and has never taken these medications, this trial may help find the best treatment approach.
This study checks if Alzheimer’s-related proteins (amyloid and tau) can be found in stool samples. It may help develop a simple, non-invasive way to detect Alzheimer’s disease.
This trial tests whether a special form of a dietary fat called tricaprilin can help people with mild-to-moderate Alzheimer's disease. It may provide an alternative or add-on to current treatments to help with memory and thinking.
This study tests a new drug called NSC001 for people with mild to moderate Alzheimer's. It checks if the drug is safe and if it might help slow memory decline. You'll need a caregiver who can join you at visits and help track your progress.
This trial tests a special supplement combination designed to support brain energy use in people with Alzheimer's. It aims to see if the supplement can help slow cognitive decline.
This study tests whether a medicine called NPC-1 can help people with mild memory or thinking problems or early-stage Alzheimer's. It looks at a blood marker to see if the treatment may slow down the disease.
Hear when a new Alzheimer Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.